Schuldink, Ilona, I (2021) α-synuclein immunotherapy as a suitable treatment for Parkinson disease. Bachelor's Thesis, Biology.
|
Text
bBIO_2021_SchuldinkI.pdf.pdf Download (485kB) | Preview |
|
![[img]](https://fse.studenttheses.ub.rug.nl/style/images/fileicons/text.png) |
Text
toestemming.pdf Restricted to Registered users only Download (161kB) |
Abstract
At the current moment in time, the only way to treat Parkinson’s disease (PD) is via symptomatic treatments that involve the dopaminergic pathway. This way of treatment only affects part of the motor symptoms of the patients. It is currently investigated if other types of treatment could potentially stop or halt the progression of PD. Via the idea of clinical trials that have been done with immunotherapy for Alzheimer’s disease, the same type of treatment is being tested for PD. For PD the immunotherapy mostly focuses on the aggregated α-synuclein formation in the neurons. The aggregated α-synuclein can transfer from neurons to other neurons via cell-to-cell transmission. This aggregated α-synuclein is an important hallmark of PD as it is thought to be the potential cause of PD. α-synuclein immunotherapy is tested in animal models, and is currently tested in clinical trials. The results thus far have been promising in reducing the aggregated α-synuclein from the brain with the use of both active and passive immunization. But there are still some concerns revolving around this new type of immunotherapy. The research question that is going to be investigated in this essay is if α-synuclein immunotherapy is a suitable treatment for PD.
| Item Type: | Thesis (Bachelor's Thesis) |
|---|---|
| Supervisor name: | Eisel, U.L.M. |
| Degree programme: | Biology |
| Thesis type: | Bachelor's Thesis |
| Language: | English |
| Date Deposited: | 08 Apr 2021 11:54 |
| Last Modified: | 08 Apr 2021 11:54 |
| URI: | https://fse.studenttheses.ub.rug.nl/id/eprint/24223 |
Actions (login required)
 |
View Item |